Coherus BioSciences Inc. (CHRS)
NASDAQ: CHRS
· Real-Time Price · USD
0.99
0.04 (4.63%)
At close: May 08, 2025, 3:59 PM
0.99
-0.03%
After-hours: May 08, 2025, 07:25 PM EDT
4.63% (1D)
| Bid | 0.96 |
| Market Cap | 115.04M |
| Revenue (ttm) | 266.96M |
| Net Income (ttm) | 28.51M |
| EPS (ttm) | 0.25 |
| PE Ratio (ttm) | 3.97 |
| Forward PE | -0.95 |
| Analyst | Buy |
| Ask | 1 |
| Volume | 780,508 |
| Avg. Volume (20D) | 1,774,557 |
| Open | 0.95 |
| Previous Close | 0.95 |
| Day's Range | 0.95 - 1.00 |
| 52-Week Range | 0.66 - 2.43 |
| Beta | 1.01 |
About CHRS
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CHRS
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
Coherus BioSciences Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago
+16.59%
Coherus BioSciences shares are trading higher afte...
Unlock content with
Pro Subscription
5 months ago
+24.82%
Coherus Biosciences shares are trading higher after the company announced an agreement to divest its Udenyca franchise for $558.4 million.
3 weeks ago · seekingalpha.com
Coherus BioSciences: Cleaning The Balance Sheet And Developing New DrugsCoherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...
2 months ago · seekingalpha.com
Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call TranscriptCoherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...